A
Ana Ruiz-Garcia
Researcher at Pfizer
Publications - 47
Citations - 1541
Ana Ruiz-Garcia is an academic researcher from Pfizer. The author has contributed to research in topics: Population & Sunitinib. The author has an hindex of 15, co-authored 45 publications receiving 1370 citations. Previous affiliations of Ana Ruiz-Garcia include Amgen.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre,Eric Raymond,Eveline Boucher,Jean Douillard,Ho Y. Lim,Jun S Kim,Magaly Zappa,Silvana Lanzalone,Xun Lin,Samuel E. DePrimo,Charles S. Harmon,Ana Ruiz-Garcia,Maria Jose Lechuga,Ann-Lii Cheng +13 more
TL;DR: Sunitinib showed pronounced toxicities at a dose of 50 mg/day in patients with unresectable HCC and the response rate was low, and the study did not meet the primary endpoint based on RECIST criteria.
Journal ArticleDOI
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam,Fiona H Blackhall,Maciej Krzakowski,Carlos H. Barrios,Keunchil Park,Isabel Bover,Dae Seog Heo,Rafael Rosell,Denis C. Talbot,Richard G. Frank,Stephen P. Letrent,Ana Ruiz-Garcia,Ian Taylor,Jane Q. Liang,A. Campbell,Joe O'Connell,Michael Boyer +16 more
TL;DR: Dacomitinib demonstrated significantly improved PFS versus erlotinib, with acceptable toxicity, in patients with advanced non-small-cell lung cancer (NSCLC), and PFS benefit was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, EGFR wild- type, and EGFR mutants.
Journal ArticleDOI
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung Jue Bang,Yoon-Koo Kang,Won Ki Kang,Narikazu Boku,Hyun Cheol Chung,Jen-Shi Chen,Toshihiko Doi,Yan Sun,Lin Shen,Shukui Qin,Wai Tong Ng,Jennifer M. Tursi,Maria Jose Lechuga,Dongrui Ray Lu,Ana Ruiz-Garcia,Alberto Sobrero +15 more
TL;DR: The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunit inib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.
Journal ArticleDOI
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Karen L. Reckamp,Giuseppe Giaccone,D. Ross Camidge,Shirish M. Gadgeel,Fadlo R. Khuri,Jeff A. Engelman,Marianna Koczywas,Arun Rajan,A. Campbell,Diana Gernhardt,Ana Ruiz-Garcia,Stephen P. Letrent,Jane Liang,Ian Taylor,Joe O'Connell,Pasi A. Jänne +15 more
TL;DR: This phase 2 trial assessed the efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) in patients with KRAS wild‐type non–small cell lung cancer (NSCLC).
Journal ArticleDOI
Pharmacokinetics in Drug Discovery
TL;DR: The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long-term viability of a pharmaceutical company since applying the right tools early in discovery will play aKey role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible.